Search

Displaying results 2031 - 2040 of 2454 in total
  1. Drug

    GPI-1485

    go.drugbank.com/drugs/DB05814
    Investigational

    GPI 1485 is a product candidate that belongs to a class of small molecule compounds called neuroimmunophilin ligands. In preclinical experiments, neuroimmunophilin ligands have been shown to repair and regenerate damaged nerves without a...

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  2. Drug

    Seletracetam

    go.drugbank.com/drugs/DB05885
    Investigational

    Seletracetam is a pyrrolidone derivative and with a structural similarity to newer generation antiepileptic drug levetiracetam. It binds to the same target as levetiracetam but with higher affinity and has shown potent seizure suppressio...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  3. Drug

    Rufinamide

    go.drugbank.com/drugs/DB06201
    Approved

    Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures.

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers
  4. Drug

    Tolvaptan

    go.drugbank.com/drugs/DB06212
    ApprovedInvestigational

    Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  5. Drug

    Vadimezan

    go.drugbank.com/drugs/DB06235
    Investigational

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  6. Drug

    Temsirolimus

    go.drugbank.com/drugs/DB06287
    ApprovedInvestigational

    Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the E...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  7. Drug

    AVE9633

    go.drugbank.com/drugs/DB06318
    Investigational

    AVE9633 is an anti-CD33 monoclonal antibody-DM4 conjugate.

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  8. Drug

    Indisulam

    go.drugbank.com/drugs/DB06370
    Investigational

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Substrates
  9. Drug

    Ambrisentan

    go.drugbank.com/drugs/DB06403
    ApprovedInvestigational

    Ambrisentan is an orally active selective type A endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension. It is approved in Europe, Canada and the United States for use as a single agent to improve e...

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  10. Drug

    Oxymetholone

    go.drugbank.com/drugs/DB06412
    ApprovedIllicit

    Oxymetholone is a synthetic anabolic steroid marketed under the brand name Anapolon by Hoffmann La Roche Limitedand used in the treatment of osteoporosis, anaemia, and as an agent to stimulate muscle growth in malnourished or underdevelo...

    Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP3A Inhibitors